Lakefront Biotherapeutics NV
Galapagos, proposed to be renamed Lakefront Biotherapeutics NV subject to shareholder approval, is a biotechnology company headquartered in Mechelen, Belgium. It develops medicines for serious diseases and uses a business development-led approach to identify, acquire, partner for or license therapeutic programs. Its strategic priorities are oncology and immunology and inflammation, and it operates as a single segment. As of December 31, 2025, its clinical pipeline included GLPG3667, an oral TYK2 inhibitor being studied in dermatomyositis and systemic lupus erythematosus, and two CAR-T candidates, GLPG5101 and GLPG5301. In January 2026, Galapagos initiated a wind-down of its cell therapy activities; once complete, its pipeline is expected to consist solely of GLPG3667. The company also receives royalties and earn-outs related to the transfer of its Jyseleca business and maintains a collaboration with Gilead that provides for licensing options and royalties on certain products.
No SEC Form 4 filings for $LKFT in the last 30 days.
See all $LKFT insider activity →Lakefront Biotherapeutics NV reported preliminary Phase 1b study data suggesting remission retention without therapy for autoimmune cytopenias. The company will present findings at ASH on December 13, with registrational studies expected in 2027.
Lakefront Biotherapeutics NV completed its share buyback program, repurchasing 107,804 shares between Oct 12-16, 2026. It now holds 1,985,157 of its own shares. The buyback was part of a plan announced in June 2026, signaling capital return and confidence.
Lakefront Biotherapeutics (LKFT) sold its preclinical CAR-T programs to Armed Cell Therapeutics for €8M upfront, with potential $230M in milestones. The sale follows the company's shift away from cell therapy. Lakefront aims to focus on T-cell engagers, with future catalysts tied to milestones and clinical progress in this area.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LKFT (Lakefront Biotherapeutics NV). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LKFT coverage spans financial news, corporate actions and mergers & acquisitions.
Early‑stage data could lift sentiment but remains speculative until full results are presented at ASH.
The buyback signals confidence and may provide modest upward pressure on the stock.
The deal provides immediate cash but removes legacy assets, likely leading to modest upside as the company pivots to T‑cell engagers.
The stake reduction may signal reduced confidence from a major shareholder and could create modest selling pressure.
The buyback modestly reduces float and signals confidence, likely providing slight upward pressure on the stock.
AlphAI scores every news story that mentions LKFT with an AI model for sentiment and relevance, and aggregates insider trades from Lakefront Biotherapeutics NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
Lakefront Biotherapeutics NV reported preliminary Phase 1b study data suggesting remission retention without therapy for autoimmune cytopenias. The company will present findings at ASH on December 13, with registrational studies expected in 2027.
1 min readLakefront Biotherapeutics NV completed its share buyback program, repurchasing 107,804 shares between Oct 12-16, 2026. It now holds 1,985,157 of its own shares. The buyback was part of a plan announced in June 2026, signaling capital return and confidence.
1 min readLakefront Biotherapeutics (LKFT) sold its preclinical CAR-T programs to Armed Cell Therapeutics for €8M upfront, with potential $230M in milestones. The sale follows the company's shift away from cell therapy. Lakefront aims to focus on T-cell engagers, with future catalysts tied to milestones and clinical progress in this area.
1 min readLakefront Biotherapeutics (LKFT) disclosed that Bank of America's stake fell below 10% of its voting rights on October 2, 2026. The bank now holds 8.54% of LKFT's outstanding shares. Analysts rate LKFT as a Hold with a $26.00 price target, while TipRanks' AI Analyst rates it as Neutral, citing strong financials but negative cash flow.
1 min readLakefront Biotherapeutics (LKFT) repurchased 117,437 of its shares for €3.05M between September 28 and October 2, 2026, as part of a share buyback program announced in June 2026. The company's shares are listed on Euronext and NASDAQ.
2 min readLakefront Biotherapeutics (LKFT) repurchased 106,060 shares for €2.8M between September 21 and 25, 2026, as part of its share buyback program. The average price paid was €26.36 per share. As of September 25, the company holds 1,633,594 of its own shares.
1 min readLakefront Biotherapeutics (LKFT) rose 3.88% to $31.36 after repurchasing 108,679 shares for about EUR 2.61M (EUR 23.16-EUR 25.44) from Sept 14-18. The company now holds 1.53M shares. Volume was 293,922 vs avg 235,203.
1 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readRBC Capital upgraded Lakefront Biotherapeutics (LKFT) to Outperform, raising its price target to $45.00 from $26.00, citing potential in its autoimmune drug gamgertamig. The firm noted clinical and regulatory risks but highlighted the drug's efficacy and safety profile. LKFT's stock currently trades at $30.19, with RBC estimating peak royalties up to $885 million.
2 min readLakefront Biotherapeutics (LKFT) plans to start registrational trials for gamgertamig in 2027, targeting autoimmune diseases like ITP and AIHA. The company acquired the asset from Ouro, citing promising efficacy and safety data. Lakefront expects to end the year with €2 billion in cash and has a share buyback program. The FDA granted Orphan Drug Designation for gamgertamig in three indications.
2 min read
